Loading…
Crescent Biopharma, Inc. is projected to rise to $24.02 by 2027, a +16% move from its current price of $20.79. CBIO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $19.77 | $20.78 | $21.85 | -0.04% |
| May 30 | $19.35 | $20.77 | $22.29 | -0.09% |
| May 31 | $19.04 | $20.76 | $22.64 | -0.13% |
| Jun 1 | $18.78 | $20.75 | $22.94 | -0.18% |
| Jun 2 | $18.55 | $20.74 | $23.20 | -0.22% |
| Jun 3 | $18.34 | $20.74 | $23.44 | -0.26% |
| Jun 4 | $18.16 | $20.73 | $23.66 | -0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.16 | $20.73 | $23.66 | -0.31% |
| Week 2 | $17.14 | $20.66 | $24.91 | -0.62% |
| Week 3 | $16.38 | $20.60 | $25.90 | -0.92% |
| Week 4 | $15.76 | $20.53 | $26.76 | -1.23% |
| Week 5 | $15.23 | $20.47 | $27.52 | -1.53% |
| Week 6 | $14.76 | $20.41 | $28.22 | -1.83% |
| Week 7 | $14.34 | $20.35 | $28.87 | -2.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Crescent Biopharma, Inc. is a biotechnology company that researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
CBIO is a biotechnology company with a current price of $20.74 and a market cap of $571.9M. It is ranked 2938 by market capitalization.
The outlook from the provided forecast shows a bullish price trajectory over the coming years, beginning with a 2026 average price of $20.74 and rising to higher levels through 2050, with a 2050 max of $686.64 and a 2050 average of $298.54. The forecast also notes robust long-term upside, with a 2050 ROI of 1339.4% and a bullish sentiment in the long horizon.
A major floor 57.0% below — a decisive break under it would weaken the trend.
The nearest floor, 13.8% below — buyers have tended to step in here.
The nearest ceiling, 29.8% above — a clean break opens room to run.
A major ceiling 48.9% above — clearing it would confirm fresh momentum.
Key CBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $20.20 | Buy | $20.28 | Buy |
| MA 10 | $19.89 | Buy | $19.97 | Buy |
| MA 20 | $19.40 | Buy | $19.84 | Buy |
| MA 50 | $18.64 | Buy | $18.47 | Buy |
| MA 100 | $14.92 | Buy | $16.59 | Buy |
| MA 200 | $13.93 | Buy | $17.11 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.27 | Neutral |
| Stoch RSI (14) | 85.52 | Sell |
| CCI (20) | 79.69 | Neutral |
| Williams %R (14) | -13.62 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 10.82 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 86.38 | Sell |
| TRIX (15) | 0.11 | Buy |
| Awesome (5,34) | -0.28 | Sell |
| Ultimate (7,14,28) | 59.44 | Neutral |
| Momentum (10) | 2.33 | Buy |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 20.88 | Sell |
| ADX (14) | 15.56 | Neutral |
| ATR (14) | 0.85 | Info |
The near-term technical picture is bullish, supported by a bullish sentiment reading. RSI14 is 60, with the 50-day moving average at $18.27 and the 200-day moving average at $13.85.
Key near-term levels show a strong basing range: support at $17.92 and resistance at $26.98. The 30-day price range spans from $14.64 to $29.38, and annualized volatility stands at 100%. The current price sits above both moving averages, indicating positive near-term momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.94 | $20.79 | $27.32 | 0% | Neutral | |
| $17.51 | $24.02 | $35.59 | +16% | Neutral | |
| $20.95 | $30.35 | $47.67 | +46% | Bullish | |
| $26.65 | $40.47 | $66.51 | +95% | Bullish | |
| $27.66 | $43.84 | $74.80 | +111% | Bullish | |
| $27.72 | $45.72 | $80.59 | +120% | Bullish | |
| $28.53 | $48.89 | $88.73 | +135% | Bullish | |
| $24.39 | $43.35 | $80.73 | +108% | Bullish | |
| $30.19 | $55.59 | $106.03 | +167% | Bullish | |
| $41.44 | $79.00 | $154.01 | +280% | Bullish | |
| $42.59 | $94.64 | $201.95 | +355% | Bullish | |
| $110.16 | $244.80 | $563.03 | +10.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $8.94 | $20.79 | $24.52 | +0.00% |
| June 2026 | $16.43 | $19.65 | $24.32 | -5.47% |
| July 2026 | $16.44 | $19.97 | $25.31 | +1.61% |
| August 2026 | $16.52 | $20.32 | $26.22 | +1.75% |
| September 2026 | $15.38 | $19.12 | $25.04 | -5.90% |
| October 2026 | $14.85 | $18.63 | $24.72 | -2.56% |
| November 2026 | $15.70 | $19.86 | $26.66 | +6.61% |
| December 2026 | $15.79 | $20.14 | $27.32 | +1.38% |
Click any year to see its month-by-month CBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Crescent Biopharma, Inc.'s 2026 outlook centres on $20.79, within a $8.94 to $27.32 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CBIO could reach as high as $35.59, with a base case around $24.02 and support toward $17.51 — roughly +16% from $20.79. A consolidation phase looks the most probable path here.
Expect CBIO to range from $20.95 to $47.67 through 2028. The $30.35 average target implies a +46% move from current prices. That is up +26% on the projected 2027 average. Momentum favours further upside here.
The CBIO price prediction for 2029 points to an average of $40.47 (low $26.65, high $66.51) — a potential gain of +95% on today's $20.79. Buyers look set to stay in control over this stretch.
In 2030, CBIO is projected to trade between $27.66 and $74.80, averaging $43.84 — a potential gain of +111% from today's $20.79. That is up +8% on the projected 2029 average. Momentum favours further upside here.
Crescent Biopharma, Inc.'s 2031 outlook centres on $45.72, within a $27.72 to $80.59 range. That is up +4% on the projected 2030 average. That marks a +120% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CBIO could reach as high as $88.73, with a base case around $48.89 and support toward $28.53 — roughly +135% from $20.79. Momentum favours further upside here.
Expect CBIO to range from $24.39 to $80.73 through 2033. The $43.35 average target implies a +108% move from current prices. That is -11% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The CBIO price prediction for 2034 points to an average of $55.59 (low $30.19, high $106.03) — a potential gain of +167% on today's $20.79. Momentum favours further upside here.
In 2035, CBIO is projected to trade between $41.44 and $154.01, averaging $79.00 — a potential gain of +280% from today's $20.79. That is up +42% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Crescent Biopharma, Inc.'s 2040 outlook centres on $94.64, within a $42.59 to $201.95 range. That is up +20% on the projected 2035 average. That marks a +355% change versus current levels. Momentum favours further upside here.
By 2050, CBIO could reach as high as $563.03, with a base case around $244.80 and support toward $110.16 — roughly +10.8x from $20.79. Buyers look set to stay in control over this stretch.
Investing $1,000 in CBIO today (≈ 48.100048 CBIO) could be worth
$11,774.73
+$10,774.73 (+1077%) by 2050 · US Dollar
Based on the average projected CBIO price of $244.8 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CBIOwould be worth at today's price.
$1,000 invested in CBIO on May 27, 2025 (≈ 43.478261 CBIO) would be worth
$903.91
-$96.09 (-9.6%) today · 0.90× · US Dollar
Based on a CBIO entry price of $23 vs. today's $20.79.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $18.91 | $1,099.42 | +9.9% |
| 1 month ago | $25.15 | $826.64 | -17.3% |
| 3 months ago | $12.35 | $1,683.4 | +68.3% |
| 6 months ago | $15.05 | $1,381.4 | +38.1% |
| 1 year ago | $23 | $903.91 | -9.6% |
| All time (5.0y) ago | $256 | $81.21 | -91.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CBIO forecast.
Our base-case forecast reaches $42.00 around 2030.
Implied market cap at $42.00: $1.16B
The multi-year forecast presents a clear bullish arc, with rising average prices and meaningful upside implied by the ROIs. By 2027, the average price is projected to be $25.08 with a 20.9% ROI and bullish sentiment.
By 2028 the average climbs to $32.96 and the ROI increases to 58.9%, continuing the bullish trend. In 2030, the average is $48.09 with a 131.8% ROI, and the sentiment remains bullish.
Looking further out, 2040 shows an average of $112.44 with a 442.1% ROI, and by 2050 the average is $298.54 with a 1339.4% ROI, while the max foreseen price for 2050 is $686.64. These figures illustrate substantial long-term upside, but are estimates and not guarantees, subject to market dynamics and other risks.
Tap a question to reveal the answer.
Avg $48.09; min $29.67; max $83.58; ROI 131.8%; sentiment BULLISH.
The forecast shows bullish sentiment in years beyond 2026, with rising average prices and positive ROIs (e.g., 2027 ROI 20.9%, 2028 ROI 58.9%, 2029 ROI 110.3%). 2026 is neutral with an avg of $20.74 and ROI of 0%.
Yes. The forecast max by 2034 is $126.37, and by 2035 it is $184.34, with higher potential later (2040 max $246.18, 2050 max $686.64).
Current price is $20.74; market cap is $571.9M.
Avg $298.54; min $134.34; max $686.64; ROI 1339.4%; sentiment BULLISH.
Crescent Biopharma, Inc. Community Discussion
0Share your Crescent Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.